Octreotida subcutánea para el tratamiento del síndrome del Blue Rubber Bled Nevus: a propósito de un caso

Beatriz López Centeno; Sira Sanz Marquez; Montserrat Pérez Encinas

doi:10.7399/fh.2015.39.6.9336

Octreotida subcutánea para el tratamiento del síndrome del Blue Rubber Bled Nevus: a propósito de un caso

Beatriz López Centeno, Sira Sanz Marquez, Montserrat Pérez Encinas

Resumen

Palabras clave

Texto completo:

PDF

Referencias

Bean WB. Blue rubber-bled nevi of the skin and gastrointestinal tract. Vascular spiders and related lesions of the skin. 1958:17-185.

Solano-Iturri G, Blanco-Sampascual S, García-Jiménez N, Díaz-Roca AB, Orive-Cura V. Síndrome del nevus azul. Una rara entidad. Gac Médica Bilbao. 2011;108:117–9.

Agnese M, Cipolletta L, Bianco MA, Quitadamo P, Miele E Staiano A. Blue rubber bleb nevus syndrome. Acta Paediatr. 2010;99:632–5.

Ramírez M, López Gutiérrez JC, Díaz M, Soto C, Miguel M, de la Torre Ramos CA et al. Síndrome de Bean o Blue rubber blue nevus syndrome. Presentación of 6 patientes. Cir Pediatr. 2010;23:241–4.

Gonzalez D, Elizondo BJ, Haslag S, Buchanan G, Steven Burdick J, Cuzzetta PC et al. Chronic Subcutaneous Octreotide Decreases Gastrointestinal Blood Loss in Blue Rubber-Bleb Nevus Syndrome. J Pediatr Gastroenterol Nutr. 2001;33:183–8.

Jin XL, Wang ZH, Xiao XB, Huang LS, Zhao XY. Blue rubber bleb nevus syndrome: A case report and literature review. World J Gastroenterol. 2014; 20:17254–9.

Zellos A, Schwarz KB. Efficacy of Octreotide in Children With Chronic Gastrointestinal Bleeding. J Pediatr Gastroenterol Nutr. 2000;30:442–6.

Sandostatin and Sandostatin LAR (Octreotide): Prescribing Information (Product Monograph). [monografía en internet]. Novartis Pharm; 2014 [citado 27-05-2015]. Disponible en: http://www.novartis.ca/asknovartispharma/download.htm?res=sandostatin_scrip_e.pdf&resTitleId=789

Wyeth J, Green L, Avigan M. Update on Pediatric Post-marketing Adverse Events: Drug Use Data for Octreotide (Sandostatin LAR®) (RCM 2007-50). [monografía en internet]. U.S. Food and Drug Administration (FDA); 2008 [citado 27-05-2015]. Disponible en: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4399b1-45%20(Sandostatin%20(octreotide)%20Safety%20Review%202008).pdf

DOI: http://dx.doi.org/10.7399%2Ffh.2015.39.6.9336